Maria Poltavskaya

Dr. Maria Poltavskaya

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2024 in IJC Heart & Vasculature
Verified
Journal Article
Open access
DMDinara F. Mesitskaya
Dinara F. Mesitskaya
ZFZaki Fashafsha
Zaki Fashafsha
MPMaria Poltavskaya
Maria Poltavskaya
DADenis Andreev
Denis Andreev
ALAnna R. Levshina
Anna R. Levshina
Philipp KopylovPhilipp Kopylov
Philipp Kopylov
Anti-cancer treatment can be fraught with cardiovascular complications, which is the most common cause of death among oncological survivors. Without appropriate cardiomonitoring during anti-cancer treatment, it becomes challenging to detect early signs of cardiovascular complications. In order to achieve higher survival rates, it is necessary to monitor oncological patients outpatiently after anti-cancer treatment administration. In this regard, we aim to evaluate the efficacy of single-lead ECG remote monitoring to detect cardiotoxicity in cancer patients with minimal cardiovascular diseases after the first cycle of polychemotherapy. The study included patients 162 patients over 18 years old with first diagnosed different types of solid tumors, planed for adjuvant (within 8 weeks after surgery) or neoadjuvant polychemotherapy. All patients were monitored, outpatiently, during 14–21 days (depending on the regimen of polychemotherapy) after polychemotherapy administration using single-lead ECG. QTc > 500 mc prolongation was detected in 8 patients (6.6 %), first-diagnosed arial fibrillation was detected in 11 patients (9 %) in period after chemotherapy administration. Moreover, left ventricular diastolic dysfunction using single-lead ECG after polychemotherapy was detected in 49 (40.1 %) patients with sensitivity 80 %, specificity 95 %, AUC 0.88 (95 % CI, 0.82–0.93). The side effects of cancer treatment may cause life-threatening risks. Early identification of cardiotoxicity plays a vital role in the solution of this problem. Using portable devices to detect early cardiotoxicity is a simple, convenient and affordable screening method, that can be used for promptly observation of patients.

11 July 2022 in Open Heart
Verified
Journal Article
Open access
PDF file
MPMaria Poltavskaya
Maria Poltavskaya
VSVictoria Sviridenko
Victoria Sviridenko
IGIlya Giverts
Ilya Giverts
IPIrina Patchenskaya
Irina Patchenskaya
IKInesa Kozlovskaya
Inesa Kozlovskaya
HSHugo Saner
Hugo Saner
Background Electrical muscle stimulation (EMS) is being evaluated as a possible alternative to exercise training to improve functional capacity in severely deconditioned patients with heart failure (HF). However, there is insufficient data on delayed effects of EMS starting early after decompensation. The aim of this study was to determine the impact of a short inpatient EMS intervention in severely deconditioned patients with HF on functional capacity and quality of life (QoL) over a follow-up period of 1 month. Methods This is a prospective randomised sham-controlled pilot study. 45 patients hospitalised for decompensated systolic HF (58% men, mean age 66.4±10.2 years) were randomised to EMS (n=22) or sham stimulation (n=23) of lower limbs starting within 3 days after admission. The intervention included 7–10 sessions lasting from 30 to 90 min. The 6-minute walking test distance (6-MWTD), Duke Activity Status Index (DASI) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) were evaluated at baseline, discharge and after 1 month. Results All patients completed the programme with good EMS tolerance. 37 patients were included in the final analysis. At discharge, 6-MWTD improved from 206,1±61,3 to 299.5±91 m, DASI from 12.1±5.6 to 18.3±7.2 and MLHFQ from 55.6±8.5 to 34.2±9 with EMS compared with smaller improvements in the sham group (p<0.05 for all). One month after discharge, improvements in the EMS group remained significant for MLHFQ (p=0.004) and DASI (p=0.042) and statistically non-significant for 6-MWTD compared with the sham group. Conclusions Short-term in-hospital EMS leads to improvements in functional capacity and QoL in selected patients early after HF decompensation that are retained over 1 month after discharge and therefore may serve as initial intervention to improve physical capacity or as a bridge to further conventional exercise training. Larger studies are required to evaluate individual responses to an early initiation of EMS in decompensated HF as well as long-term effects.

1 November 2018 in Human Physiology
Verified
Journal Article
Closed access
PDF file
MPMaria Poltavskaya
Maria Poltavskaya
VSV. P. Sviridenko
V. P. Sviridenko
IKI. B. Kozlovskaya
I. B. Kozlovskaya
ABA. V. Brand
A. V. Brand
DMDenis MD
Denis MD
ASA. L. Syrkin
A. L. Syrkin
Neuromuscular electrical stimulation (NMES) of large muscle groups in patients with stable chronic heart failure (CHF) increases physical work capacity and muscle strength. The safety and...

1 July 2021 in Human Physiology
Verified
Journal Article
Closed access
PDF file
MPMaria Poltavskaya
Maria Poltavskaya
VSV. P. Sviridenko
V. P. Sviridenko
ABA. V. Brand
A. V. Brand
DAD. A. Andreev
D. A. Andreev
YKYu. A. Koryak
Yu. A. Koryak
ETE. S. Tomilovskaya
E. S. Tomilovskaya
The article describes a series of studies of the efficacy of the method of electromyostimulation, developed under the leadership of Inesa Benediktovna Kozlovskaya for the system of countermeasures against negative space flight effects on the muscular system, in the rehabilitation of patients hospitalized with decompensated chronic heart failure. It has been shown that low-frequency neuromuscular electrical stimulation of leg muscles has a favorable effect on exercise capacity and activity of patients and the assessment of their quality of life and general well-being. The efficacy of electrical stimulation significantly exceeds placebo and is comparable to low- to medium-intensity interval bicycle exercise training. It is well tolerated, does not induce significant changes in central hemodynamics, carbohydrate and lipid metabolism, renal function, and markers of muscle damage. The method can be used in the rehabilitation of patients with heart failure who are unable or unwilling to perform conventional exercise training.

8 December 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ANAlena Novikova
Alena Novikova
MPMaria Poltavskaya
Maria Poltavskaya
MPMaria Pavlova
Maria Pavlova
PCPetr Chomakhidze
Petr Chomakhidze
VSV. M. Sotnikov
V. M. Sotnikov
DMDenis MD
Denis MD
Aim. To study the traditional risk factors for cardiovascular disease (CVD), indicators of endothelial function and exercise tolerance in patients received complex treatment for cranial and craniospinal tumors in childhood, including radiation therapy.Material and methods. We compared examination data of 48 patients who underwent treatment for brain tumors using cranial and craniospinal irradiation in childhood (mean age, 21,7±4,3 years, mean period after the end of treatment, 6,9±5,4 years), and 20 healthy volunteers. Examination methods included assessment of lipid profile, vascular stiffness and endothelial function using the Photoplethysmography and occlusion test, cardiopulmonary test, and in patients who underwent craniospinal irradiation, also echocardiography and duplex ultrasound of extracranial arteries.Results. Compared to healthy individuals, patients after a brain tumor were found to have lower blood pressure, higher heart rate (HR), significantly lower exercise performance (peak oxygen consumption, 19,8±6,4 ml×min-1×kg vs 30,3±5,8 ml×min-1×kg, p<0,0001) and a higher prevalence of dyslipidemia (56% vs 5%, p<0,0001), as well as an increase in the augmentation index, indicating higher stiffness of large vessels (-7,3±16,3 vs -20,3±7,9, p=0,001), and a trend towards a decrease in the occlusion index (p=0,051). Echocardiography and duplex ultrasound revealed no radiation-associated abnormalities.Conclusion. Determining the mechanisms and prognostic significance of the identified risk factors for CVD (dyslipidemia, decreased exercise tolerance, increased heart rate and vascular stiffness) in this category of patients requires further research. Regular monitoring of risk factors, primarily the lipid profile, and the use of preventive measures for individuals with an increased risk of CVD should be recommended.

12 January 2023 in Medical alphabet
Verified
Journal Article
Open access
PDF file
VLV. D. Levina
V. D. Levina
MPMaria Poltavskaya
Maria Poltavskaya
VSV. P. Sedov
V. P. Sedov
PCPetr Chomakhidze
Petr Chomakhidze
LBLarisa Bolotina
Larisa Bolotina
AGA. N. Gerasimov
A. N. Gerasimov
   Objective. To evaluate the alterations of Global longitudinsl strain (GLS) and it’s value for prediction of cardiotoxicity of low to moderate cumulative doses of anthracyclines.   Methods. Forty-nine women 50 ± 10 years old with breast cancer, treated with anthracyclines (cumulative dose of 251 ± 60 mg/m2) were enrolled in the study. Echocardiography with GLS measurement was performed at baseline, at the end of anthracycline treatment, then every 3 months during 1 year. Cardiotoxicity was defined as a decline in left ventricular ejection fraction (LVEF) of at least 10 % to ≤ 53 %.   Results. There was a significant increase in mean LVESV and LVEDV and decrease of GLS (р < 0,05) but not LVEF at 3 month post anthracycline treatment. Cardiotoxicity was detected in 8 patients (16 %) with moderate baseline risk. Absolute ≥ 4 % reduction of GLS during follow-up, GLS andpercent of it’s reduction from baseline to 3 month post-anthracycline were predictive of cardiotoxicity (AUC = 0,822 and 0,870, respectively). The reduction in GLS of >12,5 % from baseline at 3 month post anthracyclines was predictive of cardiotoxicity with sensitivity of 80 % and specificity of 95 %.   Conclusions. GLS and its reduction from baseline has shown predictive value for development of cardiotoxicity in patients with moderate risk treated with low-to moderate cumulative doses of antracyclines. Additional echocardiography with GLS assessment at 3–6 month after completion of anthracycline treatment may be recommended irrespective of cardiotoxicity risk.